Skip to content

Study · Animal study (in vivo) · mouse · 2011

4 results

Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice.

Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M, Canzoniero LM, Ciavardelli D, Rizzarelli E, Sensi SL

PloS one15 Mar 2011Cited by 148 (Europe PMC)

PMID21423579 (opens in a new tab)PMCIDPMC3058055 (opens in a new tab)DOI10.1371/journal.pone.0017971 (opens in a new tab)PepBankPUB-21423579
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundThe pathogenic road map leading to Alzheimer's disease (AD) is still not completely understood; however, a large body of studies in the last few years supports the idea that beside the classic hallmarks of the disease, namely the accumulation of amyloid-β (Aβ) and neurofibrillary tangles, other factors significantly contribute to the initiation and the progression of the disease. Among them, mitochondria failure, an unbalanced neuronal redox state, and the dyshomeostasis of endogenous metals like copper, iron, and zinc have all been reported to play an important role in exacerbating AD pathology. Given these factors, the endogenous peptide carnosine may be potentially beneficial in the treatment of AD because of its free-radical scavenger and metal chelating properties.MethodologyIn this study, we explored the effect of L-carnosine supplementation in the 3xTg-AD mouse, an animal model of AD that shows both Aβ- and tau-dependent pathology.Principal findingsWe found that carnosine supplementation in 3xTg-AD mice promotes a strong reduction in the hippocampal intraneuronal accumulation of Aβ and completely rescues AD and aging-related mitochondrial dysfunctions. No effects were found on tau pathology and we only observed a trend toward the amelioration of cognitive deficits.Conclusions and significanceOur data indicate that carnosine can be part of a combined therapeutic approach for the treatment of AD.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, carnosine supplementation strongly reduced hippocampal intraneuronal amyloid accumulation.

    In plain wordsIn mice with an Alzheimer disease model, carnosine reduced amyloid accumulation within hippocampal neurons.

    Peptide
    L-carnosine
    Outcome
    DecreaseHippocampal intraneuronal amyloid accumulation
    Study

    mousen: not reported in source

    3xTg-AD mouse
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that carnosine supplementation in 3xTg-AD mice promotes a strong reduction in the hippocampal intraneuronal accumulation of Aβ and completely rescues AD and aging-related mitochondrial dysfunctions.
    1 context sentence
    Summary · context
    In this study, we explored the effect of L-carnosine supplementation in the 3xTg-AD mouse, an animal model of AD that shows both Aβ- and tau-dependent pathology.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, carnosine completely rescued Alzheimer disease- and aging-related mitochondrial dysfunction.

    In plain wordsIn mice with an Alzheimer disease model, carnosine reversed disease- and aging-related mitochondrial dysfunction.

    Peptide
    L-carnosine
    Outcome
    DecreaseMitochondrial dysfunction
    Study

    mousen: not reported in source

    3xTg-AD mouse
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that carnosine supplementation in 3xTg-AD mice promotes a strong reduction in the hippocampal intraneuronal accumulation of Aβ and completely rescues AD and aging-related mitochondrial dysfunctions.
    1 context sentence
    Summary · context
    In this study, we explored the effect of L-carnosine supplementation in the 3xTg-AD mouse, an animal model of AD that shows both Aβ- and tau-dependent pathology.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, carnosine had no reported effect on tau pathology.

    In plain wordsIn mice with an Alzheimer disease model, carnosine did not affect tau pathology.

    Peptide
    L-carnosine
    Outcome
    No significant changeTau pathology
    Study

    mousen: not reported in source

    3xTg-AD mouse
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No effects were found on tau pathology and we only observed a trend toward the amelioration of cognitive deficits.
    1 context sentence
    Summary · context
    In this study, we explored the effect of L-carnosine supplementation in the 3xTg-AD mouse, an animal model of AD that shows both Aβ- and tau-dependent pathology.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, carnosine produced only a trend toward improved cognitive deficits.

    In plain wordsIn mice with an Alzheimer disease model, carnosine showed only a trend toward improved cognition.

    Peptide
    L-carnosine
    Outcome
    DecreaseCognitive deficits
    Study

    mousen: not reported in source

    3xTg-AD mouse
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No effects were found on tau pathology and we only observed a trend toward the amelioration of cognitive deficits.
    1 context sentence
    Summary · context
    In this study, we explored the effect of L-carnosine supplementation in the 3xTg-AD mouse, an animal model of AD that shows both Aβ- and tau-dependent pathology.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.